Aromatase inhibitors: their role in breast cancer
GM, 36, August, 2006
Third-generation aromatase inhibitors (AI) are already well established as the fi rst-line
treatment of advanced stage breast cancer. However, new data is emerging showing AIs to
be a possible alternative to tamoxifen in early stage breast cancer. Dr Andrew Wardley
reviews the role of AIs as a neoadjuvant, adjuvant or an extended adjuvant in this type of
breast cancer.
Comments
Write a Comment
Comment Submitted